Skip to main content

Advertisement

Table 1 Comparison of demographic characteristics of survivors and non survivors of Pseudomonas aeruginosa bacteremia

From: Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy

  Total (n = 234) Non survivors (n = 52) Survivors (n = 182) Pvalue
Age, median years (range) 57 (19 ~ 93) 60.5 (19 ~ 84) 56 (21 ~ 93) 0.35
Male sex 92 (39.3%) 23 (44.2%) 69 (37.9%) 0.41
Underlying disease
 Diabetes mellitus 47 (20.1%) 8 (15.4%) 39 (21.4%) 0.34
 Hypertension 52 (22.2%) 11 (21.2%) 41 (22.5%) 0.83
 Liver cirrhosis 13 (5.6%) 2 (3.8%) 11 (6.0%) 0.54
 Transplant 34 (14.5%) 10 (19.2%) 24 (13.2%) 0.27
 Solid organ 8 (3.4%) 1 (1.9%) 7 (3.8%)  
 Bone marrow 26 (11.1%) 9 (17.3%) 17 (9.3%)  
 Malignancy 68 (29.1%) 14 (26.9%) 54 (29.7%) 0.70
 Dialysis 11 (4.7%) 2 (3.8%) 9 (4.9%) 0.74
Neutropenia 54 (23.1%) 18 (34.6%) 36 (19.8%) 0.02
Hospitalization in the preceding 90 days 98 (41.9%) 26 (50.0%) 72 (39.6%) 0.18
APACHE II score, median (IQR) 12 (0 ~ 40) 18 (5 ~ 40) 11 (0 ~ 28) 0.0001
Charlson comobidity index, median (IQR) 3 (0 ~ 13) 4 (1 ~ 10) 4 (0 ~ 13) 0.57
Septic shock 62 (26.7%) 28 (53.8%) 34 (18.7%) 0.0001
Invasive procedure
 Central venous catheter 97 (41.5%) 36 (69.2%) 61 (33.5%) 0.0001
 Surgical drainage 39 (16.7%) 8 (15.4%) 31 (17.0%) 0.78
 Foley catheter 50 (21.4%) 28 (53.8%) 22 (12.1%) 0.0001
 Mechanical ventilator 32 (13.7%) 20 (38.5%) 12 (6.6%) 0.0001
The length of stay before bacteremia, median days (IQR) 1 (0 ~ 92) 1 (0 ~ 28) 2.5 (0 ~ 92) 0.2
Source of bacteremia     0.006
 Pneumonia 70 (29.9%) 27 (51.9%) 43 (23.6%)  
 Urinary tract 18 (7.7%) 2 (3.8%) 16 (8.8%)  
 Vascular catheter-related 4 (1.7%) 1 (1.9%) 3 (1.6%)  
 Intra-abdomen 42 (17.9%) 7 (13.5%) 35 (19.2%)  
 Postoperative wound 11 (4.7%) 1 (1.9%) 10 (5.5%)  
 Unknown 89 (38.0%) 14 (26.9%) 75 (41.2%)  
Length of hospital stay, median days (IQR) 17 (1 ~ 364) 12 (1 ~ 364) 18 (1 ~ 92) 0.08
Carbapenem resistance 118 (50.4%) 26 (50.0%) 92 (50.5%) 0.94
Multidrug resistance 6 (2.6%) 3 (5.8%) 3 (1.6%) 0.09